Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 1
1947 3
1950 5
1951 4
1952 1
1954 1
1955 1
1957 2
1958 1
1960 1
1963 1
1964 1
1969 2
1970 4
1971 1
1972 1
1973 1
1974 1
1976 4
1977 4
1978 2
1979 2
1981 2
1982 2
1983 2
1984 2
1985 2
1986 1
1987 2
1988 1
1990 1
1992 2
1994 3
1997 2
1998 1
2000 9
2001 4
2002 3
2003 3
2004 4
2005 1
2006 2
2008 1
2009 1
2011 1
2013 1
2014 2
2015 5
2016 4
2017 9
2018 9
2019 9
2020 7
2021 2
2022 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Free article. Clinical Trial.
Editorial.
Artioli G, Foà C, Sarli L. Artioli G, et al. Among authors: foa c. Acta Biomed. 2019 Jul 8;90(6-S):5-6. doi: 10.23750/abm.v90i6-S.8643. Acta Biomed. 2019. PMID: 31292410 Free PMC article.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
Editorial: a focus on Post-Graduate specializations.
Artioli G, Foà C, Sarli L. Artioli G, et al. Among authors: foa c. Acta Biomed. 2019 Mar 28;90(4-S):5-7. doi: 10.23750/abm.v90i4-S.8308. Acta Biomed. 2019. PMID: 30977743 Free PMC article.
Image processing and radiotherapy.
Bondiau PY, Malandain G, Chanalet S, Marcy PY, Foa C, Ayache N. Bondiau PY, et al. Among authors: foa c. Cancer Radiother. 2004 Apr;8(2):120-9. doi: 10.1016/j.canrad.2003.10.002. Cancer Radiother. 2004. PMID: 15132145 Review. English, French.
148 results